

**RECEIVED  
CENTRAL FAX CENTER**

**OCT 18 2006**

**REMARKS**

In the Reply to Restriction Requirement mailed September 25, 2006, applicants elected Group VXI, claims 90-92, directed to a pharmaceutical composition, and the species of formula VIII without traverse. In the present amendment, claims 1-92 are canceled and new claims 93-109 are presented for examination.


Support for claim 93 and the compounds recited in dependent claims 94-104 and 106-107 is as follows. Support for the compound of formula VIII recited in claim 93 is found, for example, on page 60 of the specification. Support for "pharmaceutically acceptable salt" recited in claim 93 is found, for example, at page 62, lines 4-5. Support for "amide formed with the C-terminal carboxylic acid" recited in claim 93 is found, for example, on page 62, lines 5-7. Support for "C-terminal amino acid of said compound exists as the free carboxylic acid" recited in claim 93 is found, for example, on page 62, lines 30-31, and in the exemplary compounds of formulae VII and VIII on page 61.

Support for claims 105, 108, and 109 is as follows. Support for "pharmaceutically acceptable carrier" recited in claim 105 is found, for example, in original claim 90. Support for "a form suitable for oral or parenteral administration" recited in claim 108 is found, for example, at page 154, line 9, and page 154, lines 26-28. Support for "enteric tablet" recited in claim 109 is found, for example, in original claim 91. No new matter has been added by the present amendment.

If there are any charges or any credits, please apply them to Deposit Account No.  
03-2095.

Respectfully submitted,

Date: October 18, 2004

  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045